These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2060 related articles for article (PubMed ID: 15143768)
1. [The history of the development and changes of quinolone antibacterial agents]. Takahashi H; Hayakawa I; Akimoto T Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768 [TBL] [Abstract][Full Text] [Related]
2. [Phototoxicity studies of pazufloxacin mesilate, a novel parenteral quinolone antimicrobial agent--in vitro and in vivo studies]. Nagasawa M; Nakamura S; Miyazaki M; Nojima Y; Hayakawa H; Kawamura Y Jpn J Antibiot; 2002 Jun; 55(3):259-69. PubMed ID: 12199110 [TBL] [Abstract][Full Text] [Related]
3. [Antibacterial activity of quinolones against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory]. Nakamura T; Shimizu C; Hirakawa K; Inui S; Okuda K; Nakata C; Fujimoto H; Okura H; Uemura Y; Takahashi H Jpn J Antibiot; 2009 Jun; 62(3):194-202. PubMed ID: 19882980 [TBL] [Abstract][Full Text] [Related]
4. [Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration]. Fukuda H; Kawamura Y Jpn J Antibiot; 2002 Jun; 55(3):270-80. PubMed ID: 12199111 [TBL] [Abstract][Full Text] [Related]
6. The fluoroquinolone antibacterials: past, present and future perspectives. Appelbaum PC; Hunter PA Int J Antimicrob Agents; 2000 Sep; 16(1):5-15. PubMed ID: 11185413 [TBL] [Abstract][Full Text] [Related]
7. [Alteration of antibacterial activity of tosufloxacin and various antibacterial agents against Streptococcus pneumoniae]. Maekawa M; Fukuda Y; Sugiura Y; Kamiyama T; Futakuchi N; Takahata M; Mitsuyama J Jpn J Antibiot; 2003 Feb; 56(1):27-35. PubMed ID: 12723396 [TBL] [Abstract][Full Text] [Related]
8. In vitro antibacterial activity of FA103, a new quinolone derivative of C-7 position with 7-perhydrodiazepinone. Imamori K; Asaoka T; Matsumoto M; Maebashi K; Matsuda H; Tahara Y Jpn J Antibiot; 1995 Dec; 48(12):1891-8. PubMed ID: 8587163 [TBL] [Abstract][Full Text] [Related]
9. [In vitro antibacterial activity of prulifloxacin, a new oral quinolone, and comparative susceptibility rate at clinical breakpoint MIC]. Inoue M; Kuga A; Kaieda S; Hosaka M; Kitasato H; Sato Y; Okamoto R; Eda T; Hoshino K; Seto I Jpn J Antibiot; 2000 Sep; 53(9):593-608. PubMed ID: 11214999 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and antibacterial activity of quinolone-based compounds containing a coumarin moiety. Emami S; Foroumadi A; Faramarzi MA; Samadi N Arch Pharm (Weinheim); 2008 Jan; 341(1):42-8. PubMed ID: 18072241 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents. Inagaki H; Miyauchi S; Miyauchi RN; Kawato HC; Ohki H; Matsuhashi N; Kawakami K; Takahashi H; Takemura M J Med Chem; 2003 Mar; 46(6):1005-15. PubMed ID: 12620077 [TBL] [Abstract][Full Text] [Related]
12. [In vitro activities of levofloxacin and other antibiotics against fresh clinical isolates]. Matsuzaki K; Koyama H; Chiba A; Omika K; Harada S; Sato Y; Hasegawa M; Kobayashi I; Kaneko A; Sasaki J Jpn J Antibiot; 1999 Sep; 52(9):571-84. PubMed ID: 10746192 [TBL] [Abstract][Full Text] [Related]
13. [In vitro antibacterial activity of prulifloxacin, a new oral fluoroquinolone]. Araake M; Hara T; Watabe H; Nishino T Jpn J Antibiot; 2002 Dec; 55(6):778-90. PubMed ID: 12621732 [TBL] [Abstract][Full Text] [Related]
14. In vitro properties of the newer quinolones. Nakanishi N; Kojima T; Fujimoto T; Mitsuhashi S Prog Drug Res; 1992; 38():19-28. PubMed ID: 1609115 [TBL] [Abstract][Full Text] [Related]
15. Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin. Kocsis B; Domokos J; Szabo D Ann Clin Microbiol Antimicrob; 2016 May; 15(1):34. PubMed ID: 27215369 [TBL] [Abstract][Full Text] [Related]
16. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
17. Development of the quinolones. Andersson MI; MacGowan AP J Antimicrob Chemother; 2003 May; 51 Suppl 1():1-11. PubMed ID: 12702698 [TBL] [Abstract][Full Text] [Related]
18. [Role of new quinolones in the treatment of mycobacteriosis]. Kekkaku; 2003 Sep; 78(9):601-4. PubMed ID: 14577348 [TBL] [Abstract][Full Text] [Related]
19. [In vitro and in vivo antibacterial activities of pazufloxacin mesilate, a new injectable quinolone]. Nomura N; Mitsuyama J; Furuta Y; Yamada H; Nakata M; Fukuda T; Yamada H; Takahata M; Minami S Jpn J Antibiot; 2002 Aug; 55(4):412-39. PubMed ID: 12378871 [TBL] [Abstract][Full Text] [Related]
20. Discovery of (3S)-amino-(4R)-ethylpiperidinyl quinolones as potent antibacterial agents with a broad spectrum of activity and activity against resistant pathogens. Hu XE; Kim NK; Gray JL; Almstead JI; Seibel WL; Ledoussal B J Med Chem; 2003 Aug; 46(17):3655-61. PubMed ID: 12904069 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]